“Frank” Talk On Drug Pricing: HHS Official Sees Value-Based Pricing As Area Of Common Interest
This article was originally published in RPM Report
Executive Summary
The most likely next step in executive branch action on drug pricing will be testing approaches to value-based pricing in categories where pharmaceutical companies are willing participants. That appears to be the message from an HHS official speaking at a DC policy event.
You may also be interested in...
Taking Big Pharma’s R&D Argument Literally: Cut Prices, Or Increase Spending?
Former Obama Administration official offers sophisticated and complicated approach to value-based pricing, tied back to drug development costs. The complexity alone makes the idea a non-starter for the current Administration, but it also begs the question of whether it would be more likely to cut costs – or just increase R&D spending?
Thinking Outside The Box On Rx Pricing: From Vaccines To Part D Bundling
Former FDA Deputy Commissioner Sharfstein suggests Vaccine-For-Children model for high value drug purchasing programs during Johns Hopkins drug pricing conference. Bundled payments in Part D is another option put on the table. Medicare head Cavanaugh explains why that option is much harder to accomplish.
Thinking Outside The Box On Rx Pricing: From Vaccines To Part D Bundling
Former FDA Deputy Commissioner suggest Vaccine-For-Children model for high value drug purchasing programs during Johns Hopkins drug pricing conference. Bundled payments in Part D is another option put on the table. Medicare head Cavanaugh explains why that option is much harder to accomplish.